Article info

Download PDFPDF
Intensive Therapy in Newly Diagnosed Type 2 Diabetes

Authors

  • Lindsay B. Harrison From the Divisions of *Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, †Biostatistics, Department of Clinical Sciences, ‡Mineral Metabolism, Department of Internal Medicine, and §Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX. PubMed articlesGoogle scholar articles
  • Beverley Adams-Huet From the Divisions of *Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, †Biostatistics, Department of Clinical Sciences, ‡Mineral Metabolism, Department of Internal Medicine, and §Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX. PubMed articlesGoogle scholar articles
  • Xilong Li From the Divisions of *Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, †Biostatistics, Department of Clinical Sciences, ‡Mineral Metabolism, Department of Internal Medicine, and §Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX. PubMed articlesGoogle scholar articles
  • Philip Raskin From the Divisions of *Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, †Biostatistics, Department of Clinical Sciences, ‡Mineral Metabolism, Department of Internal Medicine, and §Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX. PubMed articlesGoogle scholar articles
  • Ildiko Lingvay From the Divisions of *Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, †Biostatistics, Department of Clinical Sciences, ‡Mineral Metabolism, Department of Internal Medicine, and §Department of Clinical Sciences, UT Southwestern Medical Center, Dallas, TX. PubMed articlesGoogle scholar articles
  1. Received December 2, 2013, and in revised form January 19, 2014.
  2. Accepted for publication January 23, 2014.
  3. Reprints: Ildiko Lingvay, MD, MPH, MSCS, Division of Endocrinology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8857. E-mail: Ildiko.Lingvay{at}UTSouthwestern.edu.
  4. Partly supported by an investigator-initiated trial grant from Novo Nordisk, Inc to I.L. Novo Nordisk, Inc played no role in the study design, conduct, or analysis, nor in preparation or final approval of the article. I.L. was supported by NIH 1K23RR024470 and B.A.H. by NIH UL1RR024982. L.B.H., B.A.H., and X.L. have nothing to declare. I.L. serves on the scientific advisory board of Novo Nordisk, Inc and has received research funding, payable to the University of Texas Southwestern Medical School, from Novo Nordisk and GI Dynamics. P.R. has received research support, payable to the University of Texas Southwestern Medical Center, from Amgen Inc, Amylin Pharmaceuticals, Andromeda Biotech Ltd, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Gilead Sciences Inc, Intarcia, Eli Lilly and Company, Novo Nordisk, Pfizer Inc, Reata Pharmaceuticals, and Rhythm Pharmaceuticals Inc. P.R. is an advisor of Amgen and Janssen and is on the Speakers’ Bureau for Janssen. No other potential conflicts of interest relevant to this article were reported.
View Full Text

Citation

Harrison LB, Adams-Huet B, Li X, et al
Intensive Therapy in Newly Diagnosed Type 2 Diabetes

Publication history

  • First published December 15, 2015.
Online issue publication 
December 15, 2015

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.